Malignant: Esophageal Cancers
Worldwide, the incidence of new esophageal cancers is 440,000, and new deaths are 442,000 making esophageal cancer ranked ninth and sixth as the most common cancer and most frequent cancer-related cause of death, respectively. Esophageal carcinoma can be squamous cell carcinoma or adenocarcinoma, the latter increasing in frequency is North America and Europe. Obesity and reflux disease have been attributed to the cause.
Patients with esophageal cancer frequently present with dysphagia and weight loss. Once suspected, esophagography and endoscopy are diagnostic. Esophageal cancers are staged using endoscopic ultrasonography and computed tomography to assess for depth of invasion, nodal disease, and distant metastatic disease.
Early-stage esophageal cancers can be treated endoscopically avoiding the need for other modalities, while locoregionally advanced tumors require chemotherapy with radiation followed by surgery. Surgery requires esophagectomy and partial gastrectomy with replacement of the resected esophagus with a suitable tubularized replacement conduit, most commonly the stomach. Three methods of performing esophagectomy are described including the transhiatal, Ivor Lewis, and McKeown. Each technique has specific advantages and disadvantages, but preference for either technique is largely based on the surgeon preference.
Expectation, outcomes, and potential complications of esophageal surgery as well as rationale for various surgical techniques are discussed in detail.
KeywordsMinimally invasive esophagectomy Open esophagectomy Laparoscopy Esophageal cancer Minimally invasive surgery McKeown esophagectomy Ivor Lewis
- 17.Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. Hoboken: Wiley-Blackwell; 2016.Google Scholar
- 18.Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–9.CrossRefGoogle Scholar
- 19.National Comprehensive Cancer Network. Esophageal cancer (Version 2.2017). https://www.nccn.org/professionals/physician_gls/pdf/esophageal
- 20.Pech O, May A, Manner H, Behrens A, Pohl J, Weferling M, Hartmann U, Manner N, Huijsmans J, Gossner L, Rabenstein T, Vieth M, Stolte M, Ell C. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology. 2014;146(3):652–660.e1.CrossRefGoogle Scholar
- 22.Yerokun BA, Sun Z, Yang CJ, Gulack BC, Speicher PJ, Adam MA, D’Amico TA, Onaitis MW, Harpole DH, Berry MF, Hartwig MG. Minimally invasive versus open esophagectomy for esophageal cancer: a population-based analysis. Ann Thorac Surg. 2016;102(2):416–23. https://doi.org/10.1016/j.athoracsur.2016.02.078. Epub 2016 May 4.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.van der Sluis PC, Ruurda JP, van der Horst S, Verhage RJ, Besselink MG, Prins MJ, Haverkamp L, Schippers C, Rinkes IH, Joore HC, Ten Kate FJ, Koffijberg H, Kroese CC, van Leeuwen MS, Lolkema MP, Reerink O, Schipper ME, Steenhagen E, Vleggaar FP, Voest EE, Siersema PD, van Hillegersberg R. Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer, a randomized controlled trial (ROBOT trial). Trials. 2012;13:230.CrossRefGoogle Scholar
- 27.Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452–66.CrossRefGoogle Scholar